|
" Placebos and nocebos in headaches / "
Dimos D. Mitsikostas, Fabrizio Benedetti, editors.
| Document Type
|
:
|
BL
|
| Record Number
|
:
|
859931
|
| Title & Author
|
:
|
Placebos and nocebos in headaches /\ Dimos D. Mitsikostas, Fabrizio Benedetti, editors.
|
| Publication Statement
|
:
|
Cham, Switzerland :: Springer,, 2019.
|
| Series Statement
|
:
|
Headache,
|
| Page. NO
|
:
|
1 online resource (ix, 142 pages) :: illustrations (some color)
|
| ISBN
|
:
|
303002976X
|
|
|
:
|
: 3030029778
|
|
|
:
|
: 9783030029760
|
|
|
:
|
: 9783030029777
|
|
|
:
|
3030029751
|
|
|
:
|
9783030029753
|
| Contents
|
:
|
Intro; Foreword; Preface; Contents; Chapter 1: Patient-Centred Care in Headaches; 1.1 Introduction; 1.2 The Attempt of a Definition of Patient-Centred Care (PCC); 1.3 The Importance of Recognizing Patients' Health Problems as They See Them as Headache Patients; 1.4 General Aspects of PCC; 1.5 PCC in Headaches; 1.6 Nocebo in PCC; 1.7 Placebo in PCC; 1.8 Successful Headache Management; 1.9 Conclusion; References; Chapter 2: Unmet Needs in Headache Management; 2.1 Acute Treatment in Migraine; 2.2 Preventive Treatment in Migraine; 2.3 Physician-Patient Communication: Treatment Decision-Making
|
|
|
:
|
2.13 Placebo and Nocebo Effects in Headache ManagementReferences; Chapter 3: Mechanisms of Pain and Headache; 3.1 Introduction; 3.2 Functional and Molecular Neuroplasticity in Chronic Pain; 3.3 Functional and Structural Neuroplasticity in Headaches and Migraine; 3.4 Molecular and Neuroplasticity and Metabolic Changes in Headaches and Migraine; 3.5 Concluding Remarks; References; Chapter 4: Mechanisms of Placebo and Nocebo; 4.1 Introduction; 4.2 Psychological Mechanisms; 4.3 Neuroanatomical and Neurochemical Underpinnings; 4.4 Clinical Implications; 4.5 Conclusions; References
|
|
|
:
|
2.4 Patients' Expectations: What Migraineurs Want2.5 Barriers in Episodic Migraine Management; 2.6 Barriers in Chronic Migraine Management; 2.7 Treatment Optimization and Progression from EM to CM; 2.8 Acute Migraine Treatment: Triptans; 2.9 Triptan Discontinuation; 2.10 How to Improve the Efficacy of Triptans; 2.10.1 Response Predictors; 2.10.2 Choice of the First-Line Therapy; 2.10.3 Time to Treatment; 2.10.4 Switching Acute Treatment; 2.10.5 Adding Additional Acute Treatments to Current Triptan Therapy; 2.11 Unmet Needs in EM Patients; 2.12 Unmet Needs in CM Patients
|
|
|
:
|
6.6 Can the Placebo Response Be Mitigated?6.7 Conclusion and Implications for Study Design; References; Chapter 7: Nocebo in Headache Treatment; 7.1 Introduction; 7.2 Methodology to Estimate Nocebos in RCTs for Primary Headaches; 7.3 Nocebos in RCTs for Primary Headaches; 7.4 Q-No Questionnaire; 7.5 Nocebos in Headache Outpatient Sufferers; 7.6 Factors Influencing Nocebos in Headaches; 7.7 Management of Nocebos in Clinical Practice; 7.8 Conclusions; References; Chapter 8: Placebos and Nocebos in Migraine: Children and Adolescents; 8.1 Introduction; 8.2 Pediatric Migraine
|
|
|
:
|
Chapter 5: The Special Case of High-Altitude Headache5.1 High-Altitude Headache: Causes and Pathophysiology; 5.2 The High-Altitude Model; 5.3 Can Placebos and Nocebos Affect Headache at High Altitude?; 5.4 Conclusions; References; Chapter 6: Placebo Response in Human Models of Headache; 6.1 Introduction; 6.2 The Rationale for Using Human Experimental Migraine Studies; 6.3 Placebo Response in Human Experimental Models; 6.4 Placebo in Relation to Vascular Effects in Human Experimental Studies; 6.5 Prevention of Experimentally Induced Headache and Migraine
|
| Abstract
|
:
|
This book discusses the role of placebos and nocebos in the treatment of headache disorders. These disorders are usually treatable, but safety and tolerability issues mean that available preventive treatments have often limited success, even in the right hands - one in five patients treated with a migraine preventive pharmaceutical agent discontinues treatment for those reasons. The nocebo effect plays a role here, with patients' negative expectation and previous unpleasant treatment experiences creating negative belief in the treatment's benefits and safety, which in turn limits treatment outcomes and adherence significantly. In RCTs on migraine prevention, one in 20 patients treated with a placebo discontinued treatment because of adverse events, indicating a considerable nocebo effect; the fewer potential adverse events described in the consent form, the smaller the nocebo effect. As such, physicians treating headache sufferers should acknowledge nocebo as a significant cofactor for treatment adherence and failure, and plan techniques to limit the effects, such as patient education and close follow-up. This highly informative and painstakingly presented book provides scientific insights for professionals and scholars with an interest in internal medicine, neurology and pain medicine.
|
| Subject
|
:
|
Headache-- Treatment.
|
| Subject
|
:
|
Placebos (Medicine)
|
| Subject
|
:
|
Headache-- Treatment.
|
| Subject
|
:
|
Placebos (Medicine)
|
| Dewey Classification
|
:
|
616.8/491
|
| LC Classification
|
:
|
RC392
|
| Added Entry
|
:
|
Benedetti, F., (Fabrizio)
|
|
|
:
|
Mitsikostas, Dimos D.
|
| |